PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• Treatments: Lenograstim

Criteria

Inclusion Criteria:

• Patients with age between 18 and 70 years

• diagnosis of breast cancer patients

• chemotherapy naive

• Karnofsky Performance Status ≥ 70

• Written informed consent are acquired

Exclusion Criteria:

• uncontrolled infection

• Have accepted radiotherapy within 4 weeks before anticipated the study

• pregnancy

• Other situations that investigators consider as contra-indication for this study